. Author manuscript; available in PMC: 2012 Oct 1.

Published in final edited form as: Lifetime Data Anal. 2011 Jun 26;17(4):566–593. doi: 10.1007/s10985-011-9199-8

Table 4.

Estimates of ${\hat{β}}_{PH}$ and ${\hat{β}}_{1}$ , ${\hat{β}}_{2}$ and ${\hat{β}}_{3}$ on the ACTG 175 data (RE is the relative efficiencies with respect to ${\hat{β}}_{1}$ .)

		Estimate	Standard Error	RE
ZDV monotherapy and ZDV + ddI	${\hat{β}}_{PH}$	−0.703	0.124	1.01
	${\hat{β}}_{1}$	−0.689	0.124	1.00
	${\hat{β}}_{2}$	−0.724	0.120	1.07
	${\hat{β}}_{3}$	−0.721	0.117	1.12

ZDV monotherapy and ZDV + zalcitabine	${\hat{β}}_{PH}$	−0.640	0.121	1.01
	${\hat{β}}_{1}$	−0.638	0.122	1.00
	${\hat{β}}_{2}$	−0.617	0.114	1.15
	${\hat{β}}_{3}$	−0.590	0.111	1.21

ZDV monotherapy and ddI monotherapy	${\hat{β}}_{PH}$	−0.528	0.116	1.01
	${\hat{β}}_{1}$	−0.525	0.116	1.00
	${\hat{β}}_{2}$	−0.536	0.111	1.10
	${\hat{β}}_{3}$	−0.509	0.109	1.14